Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

This study is looking into a new medicine called efgartigimod for adults who have a blood condition called primary immune thrombocytopenia (ITP). ITP causes low levels of platelets, which are important for blood clotting. The main goal is to find out how well efgartigimod works (its 'efficacy') and if it's safe to use. You'd first have a check-up period, then be randomly assigned to receive either the study drug (efgartigimod) or a dummy treatment (placebo) for up to 24 weeks. After this, everyone will receive efgartigimod for about two years, followed by a period where no study drug is given. The whole study could last up to 138 weeks.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
argenx
Meta de inscrição
69
Iniciar
18 Oct 2024
Conclusão estimada
01 Jun 2028

Sobre o que é este estudo?

This study is designed to learn more about a new treatment, efgartigimod, for adults living with primary immune thrombocytopenia, often just called ITP. ITP is a condition where your body's immune system mistakenly attacks and destroys its own platelets, which are tiny cells in your blood that help it clot. If you don't have enough platelets, you can bruise easily or bleed more than usual.

The researchers want to see if efgartigimod can help increase platelet counts and reduce bleeding in people with ITP. They also want to understand if the medicine is safe and doesn't cause too many side effects. Comparing it to a placebo (a treatment that looks like the real thing but has no active medicine) helps them truly see the effect of efgartigimod.

Participating could mean you receive a new treatment that might help your ITP, or you might receive a placebo at first. After a certain period, everyone in the study will get the active medicine. This type of research is really important because it helps doctors find better ways to manage conditions like ITP and improve the lives of people living with them.

Pontos principais

  • This study is testing a new medicine for adults with ITP.
  • It aims to see how well efgartigimod works and if it's safe.
  • Participation involves receiving either the study drug or a placebo at first.
  • Everyone on the study will get the active medicine eventually.
  • The study involves regular clinic visits for IV treatments and check-ups.
  • The total study duration could be up to 2.5 years.

Quem pode ser elegível?

To join this study, you need to be at least 18 years old. You must also have had primary ITP for more than a year and have a low platelet count. In the past, you should have tried at least one common ITP treatment (like steroids, IVIg, or other specific medicines) and it didn't work well enough.

There are also some reasons why you might not be able to join. For instance, if you have other serious health problems or a different type of ITP (not primary ITP), or if you have certain related conditions like another serious autoimmune disease or a current severe bleeding problem, you wouldn't be able to take part.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem pelo menos 18 anos?
  2. Have you had primary ITP for more than one year?
  3. Do you currently have a low platelet count (less than 30)?
  4. Have you tried at least one previous ITP treatment (like steroids or IVIg) and it didn't work well enough?
  5. Have you had at least one platelet count of 50 or higher in response to a past ITP treatment (like prednisone, IVIg, etc.) in the last three years?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, you'll first have a screening period of up to two weeks to make sure the study is right for you. If you qualify, you'll be randomly assigned to one of two groups: either you'll receive efgartigimod, or you'll receive a placebo (a dummy medicine). You won't know which one you're getting, and neither will your study doctor, during this 'double-blind' period, which lasts up to 24 weeks.

After this initial phase, everyone will then receive efgartigimod for about 52 weeks. If you and your doctor agree, you might continue receiving efgartigimod for another 52 weeks. Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests, and to receive your study medication, which will be given as an IV (into a vein). After all the treatment periods, there will be a follow-up period of about eight weeks where you won't be taking the study drug. The total time you'd be involved in the study could be up to 138 weeks (roughly 2.5 years).

Riscos e benefícios potenciais

Taking part in a clinical trial offers potential benefits, such as receiving close medical care and access to a new treatment before it's widely available. However, there are also potential risks, including side effects from the study medication or the possibility that the treatment may not work for you. As with any medical procedure, there could be discomfort from blood tests or IV injections. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care, and this will be fully explained before you agree to take part.

Localizações (94)

  • Mayo Clinic Hospital Scottsdale
    Código postal verificado
    Phoenix, Estados Unidos· Recrutamento
  • University of Southern California Norris Comprehensive Cancer Center
    Código postal verificado
    Los Angeles, Estados Unidos· Recrutamento
  • Sharp Memorial Hospital
    Código postal verificado
    Oceanside, United States· Recrutamento
  • University of Colorado Hospital
    Código postal verificado
    Aurora, Estados Unidos· Recrutamento
  • Yale University School of Medicine
    Código postal verificado
    New Haven, Estados Unidos· Recrutamento
  • Georgetown University Hospital
    Código postal verificado
    Washington D.C., Estados Unidos· Recrutamento
  • The University of Chicago Medicine
    Código postal verificado
    Chicago, Estados Unidos· Recrutamento
  • The University of Iowa Hospitals & Clinics
    Código postal verificado
    Iowa City, Estados Unidos· Recrutamento
  • Tulane University
    Código postal verificado
    Nova Orleans, Estados Unidos· Recrutamento
  • Henry Ford Health
    Código postal verificado
    Detroit, Estados Unidos· Recrutamento
  • Universidade de Minnesota
    Código postal verificado
    Minneapolis, Estados Unidos· Recrutamento
  • Regional Cancer Care Associates, LLC (RCCA)
    Código postal verificado
    Little Silver, United States· Recrutamento

Perguntas frequentes

What is primary immune thrombocytopenia (ITP)?

ITP is a blood disorder where your immune system attacks and destroys your own platelets, which are essential for blood clotting. This can lead to easy bruising or bleeding.

What is efgartigimod?

Efgartigimod is the new experimental medicine being tested in this study to see if it can help increase platelet counts in people with ITP.

O que é um 'placebo'?

A placebo is a treatment that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers understand the true effect of the active medication.

Como o medicamento será administrado?

The study medicine, efgartigimod (or the placebo), will be given as an intravenous (IV) infusion, meaning it will be delivered directly into a vein.

Quanto tempo estarei no estudo?

The study could last for up to 138 weeks, which is about two and a half years, including treatment and follow-up periods.

Como saber mais

Sabine Coppieters, MD

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study to Assess the Efficacy and Safety of Efgartigimod IV…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.